Lexicon Pharmaceuticals LXRX Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate.
The official record: Lexicon Pharmaceuticals’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount?
- Lexicon Pharmaceuticals (LXRX) reported effective income tax rate reconciliation at federal statutory income tax rate, amount of -$2.64M in Q4 2025.
- How has Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount changed year-over-year?
- Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount increased by 74.9% year-over-year, from -$10.52M to -$2.64M.
- What is the long-term trend for Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount has grown at a -13.0% compound annual growth rate (CAGR), from -$18.43M to -$10.57M.
- What does effective income tax rate reconciliation at federal statutory income tax rate, amount mean?
- The absolute monetary value representing the expected income tax expense or benefit calculated by applying the federal statutory tax rate to the company's pre-tax income. This serves as the baseline figure before accounting for various tax credits, deductions, and valuation allowance adjustments.